Idm Pharma — Investor Presentation (October 2007)
33 slides from Idm Pharma's investor presentation, Oct 11, 2007
Slide 1: Safe Harbor Statement
This presentation includes forward-looking statements that reflect management's current views of future events such as statements about the expected timing of milestone events, the review of the submissions for marketing approval of our lead product candidate, mifamurtide (L-MTP-PE) by the U.S. Food
Slide 2: IDM Pharma: Immunotherapy Designed to Treat Cancer
IDM Pharma Immunotherapy Designed to Treat Cancer Founded: 1987 Headquarters: Irvine, California European Operations: Paris GMP Manufacturing: Irvine and Paris No. Employees: ~70 NASDAQ: IDMI Product Focus: Oncology Lead Product: Mifamurtide (L-MTP-PE, MEPACT(r), formerly known as Junovan) for the t
Slide 3: IDM Pharma Corporate Strategy
IDM Pharma Corporate Strategy Focus on core technologies Obtain approval and commercialize L-MTP-PE in the EU and the United States Advance product pipeline UVIDEM(r) in melanoma IDM-2101 in non-small cell lung cancer Exercise strong fiscal management Strengthen management team
Slide 4: Focus on Core Technologies
Focus on Core Technologies Destroy cancer cells by activating innate immunity L-MTP-PE for osteosarcoma - pre-registration BEXIDEM(r) for bladder cancer - in Phase 2 Prevent tumor recurrence by triggering a specific adaptive immune response UVIDEM(r) for melanoma - three Phase 2 trials IDM-2101 for
Slide 5: IDM Pharma Products Targeting Large Oncology Markets
IDM Pharma Products Targeting Large Oncology Markets SIGNIFICANT GLOBAL COMMERCIAL POTENTIAL >$13 Billion Market Opportunity Sources: Data monitor, Globocan, BioPharm Insight 2nd Qtr 3rd Qtr 4th Qtr Osteosarcoma 0.5 27.4 90 20.4 Lung 2.5 38.6 34.6 31.6 Breast 6.2 46.9 45 43.9 Colorectal 6.8 Melanoma
Slide 6: IDM Pharma Corporate Strategy
IDM Pharma Corporate Strategy Focus on core technologies Obtain approval and commercialize L-MTP-PE in the EU and the United States Advance product pipeline UVIDEM(r) in melanoma IDM-2101 in non-small cell lung cancer Exercise strong fiscal management Strengthen management team
Slide 7: L-MTP-PE Market Opportunity: Significant Opportunity Beyond Osteosarcoma
Initial market opportunity in non-metastatic osteosarcoma Represents 3% of all childhood cancers Most commonly affects children/young adults experiencing their adolescent growth spurt Survival of children with osteosarcoma has remained at 60-65% for the last 20-30 years Osteosarcoma is an orphan dis
Slide 8: L-MTP-PE Mechanism of Action
L-MTP-PE Mechanism of Action Activates Macrophages to Attack & Kill Cancer Cells L-MTP-PE activates macrophages along with release of cytokines to attack tumor cells L-MTP-PE stimulates a signaling pathway and thus expresses cytokines such as TNF-a, IL-1, IL-6, IL-8 and IL-12 In pre-clinical animal
Slide 9: L-MTP-PE MOA Induces Infiltration of Inflammatory Macrophages
L-MTP-PE MOA Induces Infiltration of Inflammatory Macrophages to Kill Cancer Cells Source: Kleinerman et al., Cancer Immunol. Immunotherapy Without L-MTP-PE With L-MTP-PE
Slide 10: L-MTP-PE Landmark Phase 3 Trial
L-MTP-PE Landmark Phase 3 Trial Highly Representative of Patient Population NCI-sponsored, cooperative group study Largest study completed in osteosarcoma 178 sites which enrolled 1/3 of eligible incident cases during study Newly diagnosed (within 30 days; age <31) 678 non-metastatic resectable dise
Slide 11: L-MTP-PE Phase 3 Trial Results
L-MTP-PE Phase 3 Trial Results Significant Improvement in DFS and Overall Survival Clinically significant effect demonstrated (2003, primary analysis) DFS (primary): p = 0.024, HR = 0.76, 95% CI (0.58, 0.98) Overall Survival: p = 0.018, HR = 0.68, 95% CI (0.49, 0.95) Six-year DFS was 66% among patie
Slide 12: L-MTP-PE Phase 3 Results: First Improvement in 20+ Years
L-MTP-PE Phase 3 Results First Improvement in DFS and Survival in 20+ Years 678 patients with non-metastatic resectable disease at diagnosis Phase 3 trial demonstrated relative reduction in the risk of recurrence of 24% and risk of death of 32% Proportion surviving relapse free Disease-Free Survival
Slide 13: L-MTP-PE Regulatory Status
L-MTP-PE Regulatory Status Submission of Amended NDA Targeted by Q1 2008 EU regulatory status Submitted EU MAA November 2006 U.S. regulatory status Submitted U.S. NDA October 2006 Submitted updated overall survival data from 2006 dataset (February 2007) ODAC committee meeting (12-2 vote against L-MT
Slide 14: L-MTP-PE Life Cycle Management Opportunity
L-MTP-PE Life Cycle Management Opportunity in Cancers Which Metastasize to the Lung MOA provides a rationale for potential benefit in treating patients with lung metastases regardless of the site of the primary tumor Cancer originating in kidney, breast, ovarian, prostate, colon and melanoma are sus
Slide 15: Corporate Strategy: UVIDEM in Melanoma
IDM Pharma Corporate Strategy UVIDEM in Melanoma Focus on core technologies Obtain approval and commercialize L-MTP-PE in the EU and United States Advance product pipeline UVIDEM(r) in melanoma IDM-2101 in non-small cell lung cancer Exercise strong fiscal management Strengthen management team
Slide 16: UVIDEM Opportunity in Melanoma
UVIDEM Opportunity in Melanoma ~100 Thousand Patients Worldwide, and Growing Worldwide Accounts for 5% of all skin cancers Accounts for 75% of all skin cancer deaths One of fastest rising cancers (>5% per year) U.S. ~60K patients diagnosed per year >8K deaths Europe (major 5 markets) ~40K patients d
Slide 17: UVIDEM Mechanism of Action
UVIDEM Mechanism of Action Activating Cellular Immunity to Attack Tumors lymphoid organ MATURE DC & lymphocyte selection B B T T T lymphocyte activation T T T T T T T T T T T UVIDEM Ab B CTL Th T T T T T T T T Induced Immune response translates into antitumor effect
Slide 18: UVIDEM Development Status
UVIDEM Development Status Plan to Begin Phase 3 in 2009 Study Population Phase 1 Phase 2 Phase 3 Status MEL-01 Stage IV Melanoma Closed MEL-201 Stage IV Melanoma Closed Ph 2 MEL-202 Stage III & IV Melanoma Ph 1/2 MEL-203 Stage II & III Melanoma Ph 1 KIN-101 Myeloma Ongoing Ph 1 Ph 2 Ongoing Closed O
Slide 19: UVIDEM MEL-202 US Phase 2 Interim Results
Interim efficacy results (ASCO 2007 abstract) Tumor Control 1 complete response, 2 partial responses and 6 stable disease PFS: 4.8 months (from apheresis) 21 patients alive (12.2-29.5 months from apheresis) Complete Histological Regression in target sites Immune response 18/29 (62%) showing increase
Slide 20: UVIDEM New Phase 2 Trial MEL-204
UVIDEM - New Phase 2 Trial Final Phase 2 Study - MEL-204 Two arm trial comparing UVIDEM versus UVIDEM + cyclophosphamide in 82 patients Primary endpoint of progression free survival Secondary endpoints of tumor response, safety and immune monitoring First patient expected to be enrolled in Q4 2007
Slide 21: Corporate Strategy: IDM-2101 in NSCLC
IDM Pharma Corporate Strategy IDM-2101 in Non-Small Cell Lung Cancer Focus on core technologies Obtain approval and commercialize L-MTP-PE in the EU and United States Advance product pipeline UVIDEM(r) in melanoma IDM-2101 in non-small cell lung cancer Exercise strong fiscal management Strengthen ma
Slide 22: IDM-2101 Opportunity in NSCLC
IDM-2101 Opportunity in NSCLC ~350k Patients with Significant Remaining Unmet Need United States NSCLC represents 87% of all lung cancers An estimated 214,000 new cases per year An estimated 160,000 patients will die from lung cancer 5 year survival of 15% Sources: Cancer Journal for Clinicians, Can
Slide 23: IDM-2101 Mechanism of Action
IDM-2101 Mechanism of Action Stimulation of CTLs to Attack NSCLC Tumor Cells Vaccine with non-small cell lung cancer (NSCLC) tumor cell antigens and immunostimulatory components to directly stimulate the production of Cytoxic T Lymphocytes (CTL) to attack NSCLC Tumor Cells IDM-2101 Contains 9 synthe
Slide 24: IDM-2101 Phase 2 Trial
IDM-2101 Phase 2 Trial Trial in Patient Population with Aggressive Disease Open label, non-randomized trial of 68 HLA-A2 positive, patients Inclusion: HLA-A2pos, stage IIIB or IV or recurrent disease, good performance status, limited tumor size Endpoints: Safety and overall survival (primary); Progr
Slide 25: IDM-2101 Interim Phase 2 Results
IDM-2101 Interim Phase 2 Results Positive Survival Signal, Well Tolerated Median survival for IDM-2101 was 19.4 months versus concurrent non-randomized controls, which was 12 months (7.4 month improvement) One-year survival was 60 percent for IDM-2101 vs. 49 percent for patients in a non-randomized
Slide 26: IDM-2101 Interim Results: 7.4 Month Increase in Median Survival
IDM-2101 Interim Phase 2 Results 7.4 Month Increase in Median Survival (vs. control) Source: IDM Pharma IDM-2101 Abstract, ASCO 2007
Slide 27: IDM-2101 Status
IDM-2101 Status Updated Data to be Presented at iSBTc November 2007 iSBTc = International Society for Biological Therapy of Cancer, November 1-4, Boston, MA Updated data from Phase 2 study to be presented at iSBTc meeting in November 2007 Phase 2 study treatment complete May 2008 Final results avail
Slide 28: Corporate Strategy: Exercise Strong Fiscal Management
IDM Pharma Corporate Strategy Exercise Strong Fiscal Management Focus on core technologies Obtain approval and commercialize L-MTP-PE in the EU and the United States Advance product pipeline UVIDEM(r) in melanoma IDM-2101 in non-small cell lung cancer Exercise strong fiscal management Strengthen man
Slide 29: Exercise Strong Fiscal Management
Exercise Strong Fiscal Management $37.3m in Cash at June 2007 Focused investment to gain approval for L- MTP-PE in EU and United States Continued development of UVIDEM in partnership with sanofi-aventis Plan future product development of IDM-2101 Current cash of $37.3m at June 2007 expected to fund
Slide 30: Corporate Strategy: Strengthen Management Team
IDM Pharma Corporate Strategy Strengthen Management Team Focus on core technologies Obtain approval and commercialize L-MTP-PE in the EU and United States Advance product pipeline UVIDEM(r) in melanoma IDM-2101 in non-small cell lung cancer Exercise strong fiscal management Strengthen management tea
Slide 31: New and Experienced Leadership Team
IDM Pharma New and Experienced Leadership Team Timothy P. Walbert, President and Chief Executive Officer Formerly VP & GM of Abbott Immunology (Led global launch of HUMIRA), Celebrex International/US Marketing Significant sales, marketing, R&D and general management experience (Wyeth, Searle/Pharmac
Slide 32: 2007 - 2008 Projected Milestones
IDM Pharma 2007 - 2008 Projected Milestones L-MTP-PE Data presented at CTOS & SIOP - November 2007 CHMP (EU) opinion on MAA December 2007 Submit U.S. NDA Amendment by Q1 2008 Gain approval EU - 1H 2008 US - 2H 2008 UVIDEM Updated MEL-202 data presented at iSBTc 11/07 Begin final Phase 2 Q4 2007 Phas
Slide 33: DRAFT Parker, Suite Irvine, CA 92618 (949) 470-4751 www.idm-pharma.com
DRAFT CONFIDENTIAL 9 Parker, Suite 100 Irvine, CA 92618 (949) 470-4751 www.idm-pharma.com